hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top
Hepatoma Res 2019;5:22.10.20517/2394-5079.2019.017© The Author(s) 2019.
Open AccessCorrection

Correction: Three primary malignancies in 17 years in a man with chronic hepatitis B

1Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

2Department of Radiology, Abdominal Imaging Division, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

3Department of Pathology, Anatomy, & Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

4Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

5Liver Disease prevention Center, Division of Gastroenterology and Hepatology Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.

Correspondence Address: Dr. Hie-Won Hann, FAASLD, Professor of Medicine, Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA. E-mail: hie-won.hann@jefferson.edu

    Views:462 | Downloads:234 | Cited:0 | Comments:1 | :0
    ...

    © The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

    The Case Report was published on 21 Jun 2019.

    The author's statement of conflict of interest was confused with the original and published incorrectly due to the negligence of the Editorial Office. Here is the correction:

    Conflict of Interest:

    Hie-Won Hann: Clinical Research Grant from Gilead, Assembly Biosciences, Arbutus and serves at the National Advisory Board of Gilead Sciences.

    Ralph Zinner: Bristol Myers Squibb, Merck

    Peter Block, Brianna Shinn, Christopher Roth, Jeffrey Baliff: No conflict of Interest.

    We, Editorial Office of Hepatoma Research apologize for any inconvenience we may cause.

    Cite This Article

    Block PD, Shinn BJ, Roth CG, Baliff JP, Zinner RG, Hann HW. Correction: Three primary malignancies in 17 years in a man with chronic hepatitis B. Hepatoma Res 2019;5:22. http://dx.doi.org/10.20517/2394-5079.2019.017

    Views
    462
    Downloads
    234
    Citations
     0
    Comments
    1

    0

    Download and Bookmark

    Download

    Download PDF Add to Bookmark

    Share This Article

    Article Access Statistics

    Full-Text Views Each Month

    PDF Downloads Each Month

    Comments

    Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.

    • Matina Lucia   
      I was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
      liver already present. I started on antiviral medications which
      reduced the viral load initially. After a couple of years the virus
      became resistant. I started on HEPATITIS B Herbal treatment from
      ULTIMATE LIFE CLINIC (www.ultimatelifeclinic.com) in March, 2020. Their
      treatment totally reversed the virus. I did another blood test after
      the 6 months long treatment and tested negative to the virus. Amazing
      treatment! This treatment is a breakthrough for all HBV carriers.

      26 Jun 2021 06:36

       0

    © 2016-2021 OAE Publishing Inc., except certain content provided by third parties